Middle east and turkey chronic liver disease therapeutics market

Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, by Disease Type (Hepatitis, Alcohol Induced Liver Disease, Liver Cancer, Fatty Liver Disease, and Others), by Drug Class (Chemotherapy Drugs, Targeted therapy, Vaccines, Immunoglobulin, and Others), by Route of Administration (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Country (Turkey, Saudi Arabia, Israel, UAE, Egypt, and Rest of Middle East and Turkey) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Request Free Sample

Feb 2022
CMI4920
211 Pages
Excel & Pdf
Pharmaceutical

Summary

Liver disease is either inherited (genetic) or is caused by factors that damage the liver such as viruses (hepatitis A, hepatitis B, and hepatitis C) and excessive alcohol consumption. Obesity is also associated with liver damage. Liver is an essential part of the body, which helps in digestion of food and controls the toxicity of substances in body. Cirrhosis is the result of liver damage, which can be life threatening and can lead to liver failure.

The increasing prevalence of chronic liver diseases such as nonalcoholic fatty liver disease, hepatitis, and others, among large population base in the Middle East region due to lifestyle diseases such as obesity and type 2 diabetes mellitus (DM) and this is expected to drive demand for drugs used in liver disease treatment, thereby propelling the market growth.

Middle East and Turkey chronic liver disease (CLD) therapeutics market size is estimated to be valued at US$ 1,015 million in 2021 and is expected to exhibit a CAGR of 5.8% over the forecast period (2021-2028).

Figure 1. Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Value (US$ Mn), by Region/Country, 2021

Figure 1.1 Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Value (US$ Mn), by Region/Country, 2028

Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Report Coverage

Report Coverage	Details
Base Year:	2020	Market Size in 2021:	US$ 1,015 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2021 to 2028
Forecast Period 2021 to 2028 CAGR:	5.8%	2028 Value Projection:	US$ 1,500 Mn
Geographies covered:	Middle East & Turkey: Turkey, Saudi Arabia, Israel, UAE, Egypt, and Rest of Middle East and Turkey
Segments covered:	By Disease Type: Hepatitis, Alcohol Induced Liver Disease, Liver Cancer, Fatty Liver Disease, Others By Drug Class: Chemotherapy Drugs, Targeted therapy, Vaccines, Immunoglobulin, Others By Route of Administration: Oral, Parenteral By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Hoffmann-La Roche AG, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB, GlaxoSmithKline Plc, Sanofi S.A, Merck & Co., Inc., AbbVie Inc., Abbott Laboratories, AstraZeneca plc., and Pfizer Inc.
Growth Drivers:	Increasing prevalence of chronic liver disease (CLD) Growing geriatric population Government and non-government awareness programs related to liver disease
Restraints & Challenges:	High cost in treatment of chronic liver disease

Figure 2. Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Share (%), by Drug Class, 2021

Figure 2.1. Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Share (%), by Drug Class, 2028

Chemotherapy Drugs segment is expected to hold largest market share in the Middle East and Turkey chronic liver disease (CLD) therapeutics market

Since cancer cells grow and multiply much faster than most of the cells in body, chemotherapy is most often utilized for cancer treatment. The increasing incidence of liver cancer and launch of novel products for cancer treatment are some of the factors, which are expected to drive the Chemotherapy Drugs segment growth. According to the International Agency for Research on Cancer (IARC), age-standardized incidence rate (ASIR) for liver cancer was 4.5 per 100,000 people in 2018 in Saudi Arabia.

Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Restraint

High cost of treatment for chronic liver diseases is a major factor, which is expected to hinder the market growth. Furthermore, owing to this factor, a large patient pool suffering from CLD is unable to avail proper treatment. The treatment for chronic liver diseases include chemotherapy, targeted therapy, vaccines, immunoglobulin, and others, which are overpriced for the patients in low and middle income countries in the (Middle East and North Africa) MENA region. For instance, the cost of surgical treatment of liver cancer in Herzliya Medical Center, Israel, is US$ 25,000 and the cost of chemotherapy starts at US$ 3,500.

Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market – Impact of Coronavirus (Covid-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020. According to the Coronavirus (COVID-19), Weekly Epidemiological Update by the World Health Organization, over 263,563,622 cases and 5,232,562 deaths due to coronavirus disease (COVID-19) were reported till December 03, 2021, across the globe.

Treatment options for cancer such as chemotherapy can weaken the immune system of cancer patients and increase the risk of getting infected. Hence, people suffering from cancer such as liver cancer are at higher risk of developing serious complications due to COVID-19 infection.

Moreover, healthcare providers are adopting telehealth solutions to conduct their services for patients with severe chronic liver disease while maintaining social distancing to combat COVID-19 pandemic without compromising the health of patients with chronic liver disease. Patients can arrange virtual appointments with their doctors for consultations. Healthcare providers are taking above mentioned measures to reduce the spread of COVID-19 infection.

Furthermore some studies also indicated that, COVID-19 was significantly associated with alcoholic liver damage. Nevertheless, impact of alcohol during COVID-19 within the alcohol consumption and ALD may impact COVID-19 pathogenesis.

Key Players

Major players operating in the Middle East and Turkey chronic liver disease (CLD) therapeutics market include Hoffmann-La Roche AG, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB, GlaxoSmithKline Plc, Sanofi S.A, Merck & Co., Inc., AbbVie Inc., Abbott Laboratories, AstraZeneca plc, and Pfizer Inc.

Table of Content

*Browse 36 market data tables and 34 figures on "Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market” – Country wide forecast to 2028.

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the market during the forecast period (2021-2028)?

Middle East and Turkey chronic liver disease (CLD) therapeutics market size is expected to be valued at US$ 1,015 million in 2021 and is expected to exhibit a CAGR of 5.8% between 2021 and 2028.

What are the major drivers for the market growth?

Increasing prevalence of chronic liver disease (CLD), growing geriatric population, Government and non-government awareness programs related to liver disease are expected to drive the market growth.

Which is the leading disease type segment in market?

Hepatitis segment is expected to hold a major market share in the market.

Which is the leading drug class segment in market?

Chemotherapy Drugs segment is expected to hold the largest market share in the market.

Which country held the largest market share in the market?

Saudi Arabia is expected to hold the highest revenue share in market.

What are the key factors hampering growth of the market?

High cost in treatment of chronic liver disease is a key factor that is expected to hamper growth of the market.